再鼎医药(09688.HK)今日盘中大涨8.64%,报27.45港元,成交额3074.33万港元,市场关注其优异的业绩表现和分析师的积极评级。
数据显示,再鼎医药截至2024年12月31日止全年收入高达3.990亿美元,同比大增50%。其旗舰产品卫伟迦®和卫力迦®销售表现亮眼,全年销售收入达到9360万美元。公司对2025年全年收入也给出了5.60亿美元至5.90亿美元的乐观指引。
在业绩利好的推动下,高盛将再鼎医药H股评级目标价从40.4港元上调至42.01港元,称2025年将是该公司的发展里程碑年。中金更是上调其港股目标价22.5%至34.41港元,并重申"跑赢大市"评级,预计公司今后将有大量利好催化剂出现,如ZLAB新药申报进展以及KarXT产品明年开始商业化等。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.